+1-888-308-5802      . .

Pfizer & Astellas Pharma to amend protocols for EMBARK & ARCHES trials

Author : Pankaj Singh | Published Date : 2018-08-24 

Pfizer & Astellas Pharma to amend protocols for EMBARK & ARCHES trials

One of the world’s largest pharmaceutical companies, Pfizer Inc. and the Japanese drug manufacturer Astellas Pharma Inc. have recently announced that they will be amending the protocols for two late-stage trials designed to test the XTANDI prostate cancer drug with an aim to speed up completion.

Reuters reports that the companies are now planning the end of the ARCHES trial late in 2018 instead of its previously anticipated end date in April 2020. The EMBARK trial is expected to be completed by middle of 2020 instead of the previously set goal of March 2021. Both trials were designed to test the efficacy and safety of XTANDI which is being developed to treat men with hormone-sensitive prostate cancer.

ARCHES is a registrational Phase 3 trial that is meant to evaluate the efficacy of enzalutamide plus androgen deprivation therapy versus androgen deprivation therapy alone in metastatic hormone-sensitive prostate cancer patients. Changes to the protocol will revise the primary endpoint of the trial which is basically radiographic progression-free survival. Revision will also occur in secondary endpoints.

EMBARK is a randomized Phase 3 evaluation of enzalutamide monotherapy, leuprolide alone and enzalutamide plus leuprolide in men with high-risk non-metastatic hormone-sensitive prostate cancer. The amendment of the protocols will mean the revision of the primary endpoint which is metastasis-free survival and the revision of several secondary endpoints which will effectively reduce the target sample size.

Steven Benner, senior VP and global therapeutic area head at Astellas, Oncology Development has been reported to say that the company worked hard to design clinical trials that facilitate innovations to reach people in need. With the amendments in EMBARK and ARCHES, patients with hormone-sensitive prostate cancer would be able to avail XTANDI sooner. Patients with non-metastatic disease will also benefit from the move as there are no approved oral treatment options available for the disease at present.

Incidentally, the U.S. Food and Drug Administration has already approved XTANDI for the treatment of castration-resistant prostate cancer.

About Author

Pankaj Singh . .

Pankaj Singh

Endowed with a post graduate degree in management and finance, Pankaj Singh has been a part of the online content domain for quite a while. Having worked previously as a U.K. insurance underwriter for two years, he now writes articles for fractovia.org and other online portals. He can be contacted at- [email protected] | https://twitter.com/PankajSingh2605

Related News

Samsung to roll out Galaxy S23 with faster, sustainable features

Samsung to roll out Galaxy S23 with faster, sustainable features

Published Date: 2023-02-03         Author: Pankaj Singh

Samsung Electronics, the South Korean technology giant, has reportedly introduced its flagship Galaxy S23 smartphone range on Wednesday, describing it as the most robust S series yet, inclusive of improved camera features, faster, and environmental-friendly features. Around 2,000 journalists and ... Read More>>

U.S. posts robust economic growth in Q4 2022 amid rising borrowing costs

U.S. posts robust economic growth in Q4 2022 amid rising borrowing costs

Published Date: 2023-01-27         Author: Pankaj Singh

The U.S. economy reportedly expanded more rapidly than anticipated in Q4, but this likely overstates the country's health considering a measure of domestic demand that surged at its weakest pace in two and a half years, highlighting the impact of increased borrowing costs. The early fourth-qu... Read More>>

North Korea pledges to get its economy on track after COVID disruption

North Korea pledges to get its economy on track after COVID disruption

Published Date: 2023-01-20         Author: Pankaj Singh

North Korea has reportedly committed to revitalizing industrial output and returning the economy to ‘normalcy’ following the disruption created by the COVID-19 outbreak. As per reports, the Korean Central News Agency (KCNA) stated on Thursday that the principal responsibility of North... Read More>>

© 2023 Fractovia. All Rights Reserved